15 citations
,
July 2023 in “EClinicalMedicine” This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.
February 2026 in “Oncology Reviews” This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.
July 2025 in “SKIN The Journal of Cutaneous Medicine” In this case study, a 64-year-old female with breast cancer undergoing ADC therapy experienced significant hair regrowth using oral minoxidil, suggesting its potential as a treatment for ADC-induced alopecia.
January 2026 in “Clinical & Translational Oncology” This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.
February 2020 in “Oncology Times” This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.
